A 5-Day Losing Streak Has ImmunityBio Stock Down 30%

ImmunityBio (IBRX) stock is on a 5-day losing streak, down 30.3% since the run began. That erased about $2.8 billion from the company's market value, which now stands at about $6.4 billion. The stock closed at $6.02 on Friday, November 13, 47.9% below its 52-week high of $11.55 and 204.0% above its low of $1.98.

IBRX Versus The S&P 500

Returns for IBRX and the S&P 500 over the streak and the periods around it, all ending Friday, November 13 and including dividends:

A Stock-Specific Slide, Or A Market Move?

Over the same 5 trading days, the S&P 500 returned +2.5% including dividends, so the slide is mostly ImmunityBio's own story rather than the market's. Over the past three months the stock is down 24.0%, a window that includes the streak; over the other 58 sessions of that window it was up 9.0%.

What The Numbers Say About The Slide

On the fundamentals, revenue grew 121.2% over the last twelve months, against a median of 7.9% for S&P 500 Health Care stocks; and its operating margin is -150.2%, versus a median of 17.4%. ImmunityBio does not have positive trailing earnings, so there is no meaningful price-to-earnings multiple to compare. The fundamentals give the sellers some support: an operating loss.

A slide like this raises an obvious follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.

Prefer the theme to the single name? A biotech ETF like XBI holds the whole group, not just this stock. It is still a concentrated bet on one theme, which is the gap the portfolio below is built to close.

Weakness In One Name Should Be Noise, Not News

For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.

Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Make the next streak, in either direction, someone else's drama.